Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15943619 | 0.84 | MEN1 (0.44) | MEN1KMT2APSMB5CYP2C9ALDH1A1 | |
| SCHEMBL9080368 | 0.84 | MEN1 (0.44) | MEN1KMT2APSMB5CYP2C9ALDH1A1 | |
| SCHEMBL12719510 | 0.84 | MEN1 (0.44) | MEN1KMT2APSMB5CYP2C9ALDH1A1 | |
| SCHEMBL12379986 | 0.84 | ALDH1A1 (0.33) | USP2TSHRALDH1A1LMNAHTT | |
| SCHEMBL18908557 | 0.82 | MEN1 (0.43) | MEN1KMT2APSMB5CYP2C9TSHR | |
| SCHEMBL21901280 | 0.82 | MEN1 (0.43) | MEN1KMT2APSMB5CYP2C9TSHR | |
| SCHEMBL11284773 | 0.82 | ALDH1A1 (0.43) | MEN1KMT2ACYP2C9USP2TSHR | |
| SCHEMBL22519382 | 0.81 | MEN1 (0.39) | MEN1KMT2APSMB5CYP2C9 | |
| SCHEMBL19343056 | 0.80 | HPGD (0.43) | KMT2APSMB5ALDH1A1HTTCYP2D6 | |
| SCHEMBL17208748 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114917763-A | Method for preparing hydrophilic PES ultrafiltration membrane by in-situ polymerization of water-soluble monomer | 浙江理工大学 | 2022-08-19 | — | — | CN | claimed |
| CN-114917763-A | Method for preparing hydrophilic PES ultrafiltration membrane by in-situ polymerization of water-soluble monomer | 浙江理工大学 | 2022-08-19 | — | — | CN | disclosed |
| CN-114917763-A | Method for preparing hydrophilic PES ultrafiltration membrane by in-situ polymerization of water-soluble monomer | 浙江理工大学 | 2022-08-19 | — | — | CN | disclosed |
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | PURDUE PHARMA L.P. | 2013-05-16 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
| EP-1597248-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-0790252-A1 | FUMARIC ACID DERIVATIVE AND POLYMER THEREOF | NOF CORPORATION (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | MEN1 4858/4885KMT2A 2003/4885PSMB5 2345/4885 |
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | TRPV1, TRPA1, TRPV2 | MEN1 4737/4885KMT2A 4676/4885PSMB5 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.